Eupraxia Pharmaceuticals Reports Promising Trial Results
Company Announcements

Eupraxia Pharmaceuticals Reports Promising Trial Results

Story Highlights

Eupraxia Pharmaceuticals (TSE:EPRX) has released an update.

Eupraxia Pharmaceuticals has announced promising results from their RESOLVE trial for the treatment of eosinophilic esophagitis, with the fifth cohort showing significant improvements in patient outcomes and histology scores. Notably, one patient achieved complete histological remission, and no serious adverse events were reported across all cohorts.

For further insights into TSE:EPRX stock, check out TipRanks’ Stock Analysis page.

Related Articles
TheFlyEupraxia reports data from RESOLVE Phase 1b/2a trial
TipRanks Canadian Auto-Generated NewsdeskEupraxia Pharmaceuticals Reports Q3 Progress and Funding
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App